Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-fibrosis
NL-OMON58866Phase 3Recruiting
- Sponsor
- 89bio
- Start
- Jan 2025
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Pegozafermin with Placebo (2 arms). Primary endpoints: Improvement in fibrosis without worsening of steatohepatitis at Week 52 and Resolution of steatohepatitis without worsening of fibrosis at Week 52. Started Jan 2025; status: recruiting.
02
Drugs
pegozafermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON58866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58866.